ArticleMolecular diagnosis & therapy2014
Influence of SREBP-2 and SCAP gene polymorphisms on lipid-lowering response to atorvastatin in a cohort of Chilean subjects with Amerindian background.
Article in Molecular diagnosis & therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 13 citations in OpenAlex.
- Mitochondrial Genetic Background May Impact Statins Side Effects and Atherosclerosis Development in Familial Hypercholesterolemia.International journal of molecular sciences · 2022Article
- Atorvastatin Increases the Expression of Long Non-Coding RNAs ARSR and CHROME in Hypercholesterolemic Patients: A Pilot Study.Pharmaceuticals (Basel, Switzerland) · 2020Article
- Article
- Endothelial lipase genetic polymorphisms and the lipid-lowering response in patients with coronary artery disease on rosuvastatin.Lipids in health and disease · 2016Article
- APOE polymorphisms contribute to reduced atorvastatin response in Chilean Amerindian subjects.International journal of molecular sciences · 2015Article
- Efficacy of ezetimibe is not related to NPC1L1 gene polymorphisms in a pilot study of Chilean hypercholesterolemic subjects.Molecular diagnosis & therapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesThis study evaluated the influence of the polymorphisms G1784C (rs4822063) and A2386G (rs12487736) of SREBP-2 and SCAP genes, respectively, on the response to atorvastatin treatment in a cohort of Chilean subjects with Amerindian background.
methodsA total of 142 hypercholesterolemic individuals underwent atorvastatin therapy (10 mg/day/1 month). Serum lipids levels before and after treatment were measured. Genotyping of the studied polymorphisms and ethnic characterization through Amerindian haplogroups (A, B, C, and D) of mitochondrial DNA was achieved by polymerase chain reaction (PCR) and PCR-restriction fragment length polymorphism (RFLP), respectively.
resultsOf all individuals, 85 % turned out to be Amerindian. C allele carriers for polymorphism G1784C, had a lower total cholesterol reduction (p = 0.015) and low-density lipoprotein cholesterol (LDL-C) (p = 0.013). No differences were found for the A2386G variant. However, those who carried both polymorphisms had a lower LDL-C reduction than carriers of just one of the variants (p = 0.030).
conclusionThe G1784C polymorphism of SREBP-2 gene affects atorvastatin response in Chilean subjects with Amerindian background, and may be an important marker for predicting efficacy of lipid-lowering therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.